Tharimmune Employees

As of December 31, 2023, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

50.00%

Revenue / Employee

n/a

Profits / Employee

-$3,616,932

Market Cap

3.08M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
China Pharma Holdings	231
iCoreConnect	70
Aditxt	47
ReShape Lifesciences	29
Theriva Biologics	22
Petros Pharmaceuticals	21
Processa Pharmaceuticals	13
Alaunos Therapeutics	1

Employee Rankings

THAR News

5 days ago - Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Accesswire
15 days ago - Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Accesswire
4 weeks ago - Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Accesswire
5 weeks ago - Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics - Accesswire
6 weeks ago - Tharimmune Announces Upcoming Conference Presentations - Accesswire
7 weeks ago - Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - Accesswire
7 weeks ago - Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Accesswire
2 months ago - Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - Accesswire

More News